We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Trump Orders Marijuana Reclassification: What It Means for the Sector
Read MoreHide Full Article
Key Takeaways
Trump signed an executive order directing agencies to reclassify marijuana from Schedule I to Schedule III.
Schedule III status could ease tax burdens, improve research access and boost industry credibility.
The order stresses marijuana's medical use but makes clear it does not legalize recreational cannabis.
On Thursday, President Trump took a historic step by signing an executive order directing federal agencies to expedite the rescheduling of marijuana at the federal level — a move that could significantly reshape the regulatory framework surrounding cannabis and recognize its medical use.
What Is an Executive Order?
An executive order is a formal written directive from the President that orders the federal government to take specific actions under existing law. In this case, President Trump ordered relevant agencies to move forward with reclassifying marijuana to Schedule III of the Controlled Substances Act (CSA).
It is important to note that an executive order is not legislation. It does not create new law or override statutes passed by Congress. Instead, it directs federal agencies to implement policy changes in a manner consistent with the current federal law.
Currently, marijuana is classified under Schedule I of the CSA — alongside substances such as heroin and LSD — which are deemed to have no accepted medical use and a high potential for abuse. Reclassifying marijuana to Schedule III would place it in the same category as drugs like ketamine and testosterone, which are recognized for medical use and carry a lower abuse risk.
In his order, President Trump emphasized the legitimate medicinal uses of marijuana, including its potential as an alternative to opioid painkillers. However, his directive was clear that it “doesn’t legalize marijuana in any way, shape or form, and in no way sanctions its use as a recreational drug.”
Alongside marijuana rescheduling, the executive order also points to a potentially meaningful development for cannabidiol (CBD). Under a new model being evaluated by the Centers for Medicare & Medicaid Services (CMS), certain CBD-based products could become eligible for Medicare coverage as early as April 2026, provided they are prescribed or recommended by a physician.
Trump’s order also urges Congress to reconsider updating the definition of “final hemp-derived cannabinoid products” to ensure that full-spectrum CBD is accessible to patients.
Why This Matters to the Marijuana Industry
For the cannabis sector, the executive order represents a long-sought regulatory milestone. Industry participants have lobbied for years to remove marijuana from Schedule I, arguing that the classification has stalled scientific research, inflated tax burdens and restricted access to traditional banking and capital markets.
A move to Schedule III could ease several of these pressures. Most notably, it may eliminate the application of IRS Rule 280E, which currently prevents cannabis businesses from deducting most operating expenses — a change that could materially improve profitability across the industry. In addition, formal medical recognition could accelerate clinical research, broaden physician acceptance and enhance credibility among institutional investors.
That said, industry experts caution that the executive order may not be as transformative as markets initially hope. Reclassification alone does not legalize marijuana federally, nor does it resolve the ongoing conflict between state and federal law. Access under Schedule III would remain strictly medical and prescription-based, offering no pathway to recreational legalization, interstate commerce or unrestricted consumer sales.
Our Take
While the executive order does not come as a surprise — given earlier reports signaling an imminent decision — it nonetheless marks a significant symbolic and regulatory shift for the cannabis industry. The announcement has already fueled renewed investor enthusiasm, with several popular cannabis stocks, such as Tilray Brands (TLRY - Free Report) , Canopy Growth Corporation (CGC - Free Report) and Curaleaf Holdings (CURLF - Free Report) , posting strong gains in recent sessions.
While the executive order represents progress, it is still not a final reform. The ultimate impact still depends on how swiftly agencies act, the way regulations are implemented and whether Congress follows through with these changes — an area where momentum has historically been uneven. For now, we advise investors to exercise caution and closely monitor how the legislation evolves in the near future.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Trump Orders Marijuana Reclassification: What It Means for the Sector
Key Takeaways
On Thursday, President Trump took a historic step by signing an executive order directing federal agencies to expedite the rescheduling of marijuana at the federal level — a move that could significantly reshape the regulatory framework surrounding cannabis and recognize its medical use.
What Is an Executive Order?
An executive order is a formal written directive from the President that orders the federal government to take specific actions under existing law. In this case, President Trump ordered relevant agencies to move forward with reclassifying marijuana to Schedule III of the Controlled Substances Act (CSA).
It is important to note that an executive order is not legislation. It does not create new law or override statutes passed by Congress. Instead, it directs federal agencies to implement policy changes in a manner consistent with the current federal law.
Currently, marijuana is classified under Schedule I of the CSA — alongside substances such as heroin and LSD — which are deemed to have no accepted medical use and a high potential for abuse. Reclassifying marijuana to Schedule III would place it in the same category as drugs like ketamine and testosterone, which are recognized for medical use and carry a lower abuse risk.
In his order, President Trump emphasized the legitimate medicinal uses of marijuana, including its potential as an alternative to opioid painkillers. However, his directive was clear that it “doesn’t legalize marijuana in any way, shape or form, and in no way sanctions its use as a recreational drug.”
Alongside marijuana rescheduling, the executive order also points to a potentially meaningful development for cannabidiol (CBD). Under a new model being evaluated by the Centers for Medicare & Medicaid Services (CMS), certain CBD-based products could become eligible for Medicare coverage as early as April 2026, provided they are prescribed or recommended by a physician.
Trump’s order also urges Congress to reconsider updating the definition of “final hemp-derived cannabinoid products” to ensure that full-spectrum CBD is accessible to patients.
Why This Matters to the Marijuana Industry
For the cannabis sector, the executive order represents a long-sought regulatory milestone. Industry participants have lobbied for years to remove marijuana from Schedule I, arguing that the classification has stalled scientific research, inflated tax burdens and restricted access to traditional banking and capital markets.
A move to Schedule III could ease several of these pressures. Most notably, it may eliminate the application of IRS Rule 280E, which currently prevents cannabis businesses from deducting most operating expenses — a change that could materially improve profitability across the industry. In addition, formal medical recognition could accelerate clinical research, broaden physician acceptance and enhance credibility among institutional investors.
That said, industry experts caution that the executive order may not be as transformative as markets initially hope. Reclassification alone does not legalize marijuana federally, nor does it resolve the ongoing conflict between state and federal law. Access under Schedule III would remain strictly medical and prescription-based, offering no pathway to recreational legalization, interstate commerce or unrestricted consumer sales.
Our Take
While the executive order does not come as a surprise — given earlier reports signaling an imminent decision — it nonetheless marks a significant symbolic and regulatory shift for the cannabis industry. The announcement has already fueled renewed investor enthusiasm, with several popular cannabis stocks, such as Tilray Brands (TLRY - Free Report) , Canopy Growth Corporation (CGC - Free Report) and Curaleaf Holdings (CURLF - Free Report) , posting strong gains in recent sessions.
While the executive order represents progress, it is still not a final reform. The ultimate impact still depends on how swiftly agencies act, the way regulations are implemented and whether Congress follows through with these changes — an area where momentum has historically been uneven. For now, we advise investors to exercise caution and closely monitor how the legislation evolves in the near future.